Can medical cannabis treat my condition?

No website can tell you whether a medicine will work for you — and any that claims to is selling something. What this guide can do is show you honestly how strong the evidence is for different conditions, so you can have a better conversation with a clinician.

The short answer

  • Nobody can answer this for you online. Only a specialist who has assessed you and read your records can.
  • The evidence varies enormously by condition — from good enough for a UK licence, to genuinely uncertain.
  • NICE could not recommend cannabis-based medicines for chronic pain outside a clinical trial.
  • Private specialists may still prescribe where an individual has unmet clinical need — a different question from population-level guidance.
  • There are real risks and side effects, and for some people the answer is that this is not a suitable treatment.

The honest answer

We cannot tell you whether medical cannabis will help your condition, and neither can any other website. Two things stand in the way: we have not assessed you, and for most conditions the underlying evidence is not strong enough to support a confident prediction for anyone.

That second point deserves more attention than it usually gets. Patient testimony about cannabis-based medicines is often powerful, and a large amount of it exists. But testimony and trial evidence answer different questions, and where trials have been done the results have frequently been more modest than the testimony suggests. Both things can be true: a treatment can be genuinely valuable to some individuals and still lack the evidence needed for a guideline to recommend it.

What the evidence actually looks like

Think of it as three tiers, not a single yes or no.

Strength of evidence for cannabis-based medicines in the UK
TierWhat it meansExamples
Licensed by the MHRA Trial evidence was strong enough for the regulator to approve a specific product for a specific use, and NICE recommends it in defined circumstances. Cannabidiol with clobazam for seizures in Lennox–Gastaut and Dravet syndromes; a THC:CBD spray for moderate-to-severe MS spasticity where other treatments failed; nabilone as an add-on for chemotherapy-induced nausea and vomiting.
Assessed and not recommended NICE looked at the evidence and concluded it did not support routine use. Chronic pain in adults. NG144 recommends not offering nabilone, dronabinol, THC or THC:CBD, and not offering CBD except within a clinical trial.
Uncertain Some observational and registry data, limited or no high-quality trial evidence. Prescribing happens case by case on unmet clinical need. Most other conditions seen in UK private practice, including many pain, neurological, gastrointestinal and mental-health conditions.

Why NICE and private specialists reach different conclusions

They are answering different questions. NICE asks: across the whole population, does the evidence justify the NHS recommending and funding this? A specialist asks: for this person in front of me, who has already tried the standard options, is a trial of treatment justified?

Both can be right at once. NICE can conclude that the evidence is too weak to recommend a treatment for everyone with chronic pain, while a specialist can lawfully prescribe an unlicensed medicine to one patient whose needs licensed medicines have not met. That is exactly the space UK law leaves open, and it is also why the responsibility on the individual prescriber is higher: they are not standing on a guideline.

What this should mean for you, practically: expect a clinician to talk about a trial of treatment with a review point, not about a solution. If nobody mentions how you will both judge whether it is working, ask.

What "may help" actually means

Where cannabis-based medicines are used, they are used to manage symptoms, not to cure disease. The symptoms most often targeted are pain, muscle spasticity, seizures, nausea, and sleep disturbance linked to an underlying condition.

A realistic good outcome usually looks like a measurable reduction in a symptom, better function or sleep, or fewer side effects than the treatment it replaced. It does not usually look like the condition going away. Beware of any material — from a clinic, a forum or a social media account — that implies otherwise.

The risks, stated plainly

Cannabis-based medicines are medicines, with side effects and risks that need weighing against any benefit.

Questions worth asking a specialist

The quality of your consultation improves sharply if you arrive with these.

  1. Given my diagnosis, how strong is the evidence for this — honestly?
  2. What symptom are we actually trying to change, and how will we measure it?
  3. How long is the trial before we decide it is not working?
  4. What side effects should I expect early on, and which ones mean stopping?
  5. How does this interact with the medicines I already take?
  6. What does this mean for my driving and my job?
  7. What happens if it helps — how do reviews and repeat prescriptions work?
  8. What would you suggest instead if this is not suitable for me?

If the answer is no

For some people, the answer will be that cannabis-based treatment is not appropriate — because the evidence for their condition is too weak, because of a safety concern, or because standard options have not yet been exhausted.

That is a legitimate clinical answer rather than a failure on your part. Ask what the alternatives are, and whether anything would change the assessment in future. If you are struggling with symptoms in the meantime, your GP, NHS 111 and specialist NHS services remain the right places to turn.

Frequently asked questions

Can medical cannabis treat my condition?

That can only be answered by a specialist who has assessed you. The evidence base differs sharply between conditions: it supported UK licences for three medicines in specific uses, while for most other conditions — including chronic pain — the evidence is limited and NICE has not been able to recommend it. A specialist weighs that evidence against your individual circumstances, your diagnosis and what has already been tried.

Why did NICE say no to cannabis for chronic pain?

NICE guideline NG144 recommends not offering nabilone, dronabinol, THC or THC:CBD combinations to manage chronic pain in adults, and not offering CBD for chronic pain except as part of a clinical trial. The committee found the clinical evidence too limited and inconsistent to show a reliable benefit, and the treatments were not cost-effective for the NHS at the prices considered.

If NICE says no, why do private clinics prescribe it?

NICE guidance advises the NHS on what to fund and recommend for a whole population. It does not remove a specialist's legal ability to prescribe an unlicensed medicine to an individual patient with an unmet clinical need. The two are answering different questions — one about population-level evidence and cost-effectiveness, the other about one person who has run out of standard options.

Does medical cannabis have side effects?

Yes. Commonly reported effects include drowsiness, dizziness, dry mouth, appetite changes, nausea and effects on concentration and memory. Less commonly, anxiety, low mood or altered perception can occur. THC-containing medicines carry a recognised risk of dependence and can trigger psychiatric symptoms in susceptible people, which is why personal or family history of psychosis is taken seriously.

Is medical cannabis a cure?

No. Where it is used, it is used to help manage symptoms — most often pain, spasticity, seizures, sickness or sleep disturbance — not to cure the underlying condition. Any claim that it cures a disease should be treated with real scepticism.

Sources and further reading

Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.

  1. NICE guideline NG144: Cannabis-based medicinal products
  2. NICE NG144: Recommendations
  3. NHS: Medical cannabis (and cannabis oils)
  4. NICE technology appraisal TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
  5. House of Commons Library briefing CBP-8355: Medical use of cannabis
  6. British Medical Association: Cannabis-based medicinal products
  7. MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use
  8. Talk to FRANK: Cannabis

Patient guide · Written by the Flora House editorial team · Last reviewed: 31 August 2026